Final week, pharmaceutical firm Moderna announced that the US Meals and Drug Administration (FDA) authorised its mRNA vaccine towards seasonal influenza (mRNA-1010 or mFLUSIVA). That is the primary vaccine of its form to be authorised for defense towards flu and is Moderna’s fourth FDA-approved product.
The approval adopted a unanimous vote by the FDA’s Vaccines and Associated Organic Merchandise Advisory Committee’s (VRBPAC) asserting that the advantages of Moderna’s investigational vaccine outweighed the dangers for flu prevention in adults aged 50–64.
“We admire the considerate assessment by the members of VRBPAC and their recognition of the medical proof supporting mRNA-1010,” mentioned Moderna CEO Stéphane Bancel in a public launch. “We imagine mRNA-1010 has the potential to supply an vital new possibility for seasonal flu prevention and additional exhibit the flexibility of our mRNA platform.”
Discovering parity
The FDA’s choice was prompted by optimistic outcomes from Moderna’s Part III medical trials (NCT05827978 and NCT06602024), which showed a positive safety profile and constant vaccine efficacy in contrast with the treatment standard.
A head-to-head between the mRNA-1010 and the “customary” flu shot confirmed that Moderna’s vaccine is 26.6% simpler. The trial additionally discovered that mRNA-1010 was extra reactogenic, that means an elevated frequency of gentle unwanted effects like ache on the web site of injection. But critical opposed occasions have been comparable between the 2 vaccines, an vital metric in security analysis.
“The FDA approval of mFLUSIVA, our fourth authorised product in the US and the primary mRNA-based flu vaccine, demonstrates the continued energy and flexibility of our mRNA platform,” continued Bancel.
“Flu stays a major public well being problem, and mFLUSIVA offers an vital new possibility for America’s seniors.”
Though now authorised to be used within the US by the FDA, the vaccine remains to be awaiting regulatory assessment in Europe, Canada, and Australia.
The landmark approval comes within the wake of ongoing discourse within the US administration surrounding mRNA-based vaccines and therapies.
“Secretary Kennedy has been clear that he believes mRNA merchandise warrant heightened scientific scrutiny. That is why this vaccine is coming into the market with a few of the strongest post-market examine commitments FDA has required,” a US Division of Well being and Human Companies (HHS) spokesperson instructed BioXconomy.
“CDC has not but issued its suggestions, and this vaccine isn’t mandated. HHS will proceed to observe the proof and make security and effectiveness knowledge publicly out there as extra info emerges.”
Moderna’s mRNA flu vaccine initially hit a stumbling block earlier this 12 months following the FDA issuing a Refusal to File letter signed by Middle for Biologics Analysis and Analysis (CBER) head Vinay Prasad in February. In a stunning about-face, the company reversed course after only one week, whereas Prasad announced his resignation from CBER one month later.
mRNA within the crosshairs
The most recent feedback from the HHS spokesperson observe a historical past of Robert F. Kennedy, Jr. and his workers sowing doubts about mRNA know-how. Final 12 months, HHS secretary RFK, Jr. announced plans to “wind down” mRNA vaccine improvement beneath the Biomedical Superior Analysis and Growth Authority (BARDA). These cuts got here regardless of mRNA therapeutics having the potential to deal with a variety of situations, from treating infertility to pancreatic cancer.
“BARDA is terminating 22 mRNA vaccine improvement investments as a result of the info present these vaccines fail to guard successfully towards higher respiratory infections like COVID and flu,” he mentioned at the time.
“HHS helps secure, efficient vaccines for each American who desires them. That’s why we’re shifting past the constraints of mRNA and investing in higher options.”
Statements like this from HHS officers have met with robust denunciations from biology and public well being consultants.
The orchestrated BARDA wind-down included outright termination of present contracts and restructuring collaborations between the HHS and a number of other pharmaceutical corporations, together with Moderna.
Bancel introduced in January 2026 that he doesn’t “foresee investing” in Part III medical trials shifting ahead because of hostility from authorities officers.
HHS assaults on mRNA continued despite estimates that the mRNA-based COVID vaccines from Moderna and Pfizer saved over 2.5 million lives between the pandemic’s onset and October 2024.
Quotes have been frivolously edited for readability.
